Letrozol Sandoz (Letrozole)

Letrozole works by reversibly binding to the aromatase enzyme’s heme group, blocking the conversion of androgens (androstenedione and testosterone) into estrogens (estrone and estradiol). This inhibition markedly reduces circulating estrogen concentrations, creating a hypo‑estrogenic environment that limits the proliferative stimulus on estrogen‑dependent breast cancer cells.

The appropriate dose of Letrozol Sandoz is determined by the prescribing physician based on the patient’s clinical condition, treatment setting and individual response. Dosage decisions are made after evaluating factors such as disease stage, prior therapies and tolerability, and the prescriber provides specific instructions on how the medication should be taken.

Letrozole is contraindicated in pregnancy because it can interfere with fetal estrogen production and cause harm to the developing embryo. It is also not recommended for breastfeeding mothers, as the drug may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception while on therapy.

To request Letrozol Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Letrozol Sandoz is a non‑steroidal aromatase inhibitor similar to anastrozole and exemestane. Compared with anastrozole, letrozole generally provides a slightly higher potency in estrogen suppression, while exemestane is a steroidal inhibitor with a different binding profile. Choice of agent depends on physician preference, patient tolerance, drug‑interaction potential and specific clinical guidelines.

Letrozol Sandoz tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in humid environments such as bathrooms, and keep the product out of reach of children. No refrigeration is required for this oral formulation.

Letrozol Sandoz is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless the prescriber provides specific instructions. Consistent daily intake helps maintain stable plasma concentrations.

The most serious risks include severe liver injury, bone fractures due to decreased estrogen, cardiovascular events such as myocardial infarction or pulmonary embolism, and rare allergic reactions like anaphylaxis. Patients should be monitored regularly for signs of hepatic dysfunction, bone health, and cardiovascular symptoms, and any severe adverse event should prompt immediate medical evaluation.

Letrozol Sandoz is not appropriate for premenopausal women, patients with known hypersensitivity to letrozole or any excipients, and individuals with severe hepatic impairment. It should also be avoided in patients receiving estrogen‑containing hormonal therapies or those with uncontrolled cardiovascular disease. Clinicians must assess each patient’s medical history before initiating therapy.